ONCY Oncolytics Biotech Inc.
-
Oncolytics Biotech Missed Consensus Estimates
Wednesday, August 12, 2026 · 12:00 AM ET
Oncolytics Biotech (ONCY) reported a loss of $0.08 per share on revenue of $0.00 million for the second quarter ended June 2026. The consensus estimate was a loss of $0.07 per share. The company missed consensus estimates by 14.29%.
Oncolytics Biotech Inc is a development stage biopharmaceutical company.
It is engaged in the discovery and development of pharmaceutical products for
the treatment of cancer.
Earnings Whisper Grade
—
Power Rating—
Reported Earnings
($0.08)
Earnings Whisper®
—
Consensus Estimate
($0.07)
Earnings Surprise
Earnings Growth
Reported Revenue
—
Revenue Estimate
—
Revenue Surprise
Revenue Growth—